Clinical Benefit and Improvement of Mitochondrial Function in Low Risk Myelodysplastic Syndrome Treated By Combination Ultra Coenzyme Q10 and L-Carnitine

Background: Structural mitochondrial abnormalities as well as alterations in gene expression of key mitochondrial proteins are well recognized in myelodysplastic syndrome (MDS), suggesting that mitochondrial dysfunction is important in the pathogenesis of this disease. Both Coenzyme Q10 and L- carnitine play an essential role in efficient cellular energy production. Clinical and cytogenetic response to high dose of Coenzyme Q10 in patients with MDS was demonstrated previously. The combination of L- carnitine and Coenzyme Q10 has shown a beneficial effect in other mitochondrial disorders. Aim: To assess the effect of combination of food supplements on the clinical course and mitochondrial function of peripheral blood cells obtained from patients with in low/intermediate- 1 risk MDS.Materials and Methods: Ultra-coenzyme Q10 (180 mg/day), L-carnitine (2000 mg/day) and a vitamin mineral complex were administered for 6 months; patients were allowed to continue treatment for an additional 6 months, if it was beneficial. Inclusion criteria were Hb Disclosures No relevant conflicts of interest to declare.